NW Bio Raises $5.5M in Streeterville Debt With 10% OID and 8% Interest
NWBO sits 23% above its 52-week low of $0.138.
Summary
Northwest Biotherapeutics signed a $5,505,000 loan with Streeterville Capital on October 26, 2026, carrying a 10% original issue discount and 8% interest, with no repayments for the first 8 months. The cash funds ongoing operations at a company that reported $595K of cash and a going concern warning in August.
Key Events · Financing and Capital Events · NWBO
-
New $5.5M Streeterville Loan
On October 26, 2026 the company entered a Commercial Loan Agreement and Note with Streeterville Capital, LLC for $5,505,000, carrying a 22-month maturity.
-
Costly Terms: 10% OID, 8% Interest
The loan carries an original issue discount of ten percent and interest at 8% per annum; prepayment at the company's election includes a 10% charge.
-
Repayment Starts June 2027
No repayments are due for the first 8 months; beginning June 26, 2027 the loan amortizes in 14 equal monthly installments of principal at 110% of the pro rata amount plus accrued interest.
-
Cash Crunch Context
The August 2026 10-Q reported $595K of cash, a $12.3M quarterly loss and a going concern warning; proceeds are earmarked for ongoing business operations.
Analysis · NWBO · Life Sciences
With $595K of cash and a going concern warning as of its August 10-Q, NW Bio needed near-term survival capital, not growth money, and this $5.5M loan fits that bill. The cost is steep: a 10% original issue discount plus 8% interest, and principal amortizes at 110% of the pro rata amount starting June 26, 2027, meaning the company repays more than it borrowed. No cash interest or principal burden arises for the first 8 months, which buys time, but the 14-month repayment schedule that follows will compete directly with trial spending. Prepayment is allowed at the company's election but carries a 10% charge, so an early refinancing is also expensive.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NWBO was trading at $0.17 on OTC in the Life Sciences sector, with a market capitalization of approximately $290M. The 52-week trading range was $0.14 to $0.34. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.